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ABSTRACT
Introduction: Despite measures to reduce the
incidence of neural tube defects (NTDs), the rate
of decline has not been as dramatic as expected.
At least 300,000 newborns worldwide are
known to be affected by NTDs each year. This
comprehensive literature review summarizes
the human and economic burden of NTDs to
patients and caregivers, with particular focus on
spina bifida (SB).
Methods: PubMed, PsycINFO, and Embase were
searched for studies from January 1976 to
November 2010 that included clinical terms,
such as NTD, and at least one patient-reported
outcome or cost term. A conceptual model was
also developed.
Results: Areas of peoples’ lives affected by SB
included physical and role functioning, activities
of daily living, bodily pain, vitality, emotional
functioning, mental health, self-esteem, self-
image, social functioning, relationships, and
sexual functioning. Areas of caregivers’ lives
affected included activities of daily living, work
impact, time consumption, parental
responsibilities (including responsibilities to
other children), confidence, feelings and
emotions, mental health, stress, social impact,
psychological adjustment, relationships (with SB
child, siblings, other family members), social
support, coping strategies, and termination
decisions. Cost burdens on patients and
caregivers also include out-of-pocket costs, lost
wages, or household production due to increased
morbidity and mortality, transportation and
other nonmedical costs.
Conclusions: This review highlights the need
to provide care and support to individuals with
SB and their caregivers. Results also emphasize
the importance of effective long-term public
health campaigns and/or newer strategies to
prevent NTDs, such as SB.
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INTRODUCTION
After cardiac abnormalities, neural tube defects
(NTDs) are the second most common group of
serious congenital anomalies [1–3]. NTDs include
spina bifida (SB) and anencephaly, as well as
cephalocele (or encephalocoele), where the brain
protrudes through a defect in the skull [4].
Each year, approximately 300,000 newborns
worldwide are born with SB or anencephaly [5,
6]. Although prevalence rates of anencephaly
and SB are similar, anencephaly results in more
abortions because it is more easily detected in
prenatal exams, and the condition is fatal to the
child [4]. Cephaloceles are less common than
anencephaly or SB, occurring in one to three per
10,000 live births [7].
NTDs typically occur when the neural tube
fails to close properly, around day 28 following
conception [4, 8–10]. Thus, closure of the neural
tube often happens before a woman knows she
is pregnant [4, 9, 11].
NTD formation has multiple etiologies.
Some cases are influenced by genetic
components. However, there are potentially
preventable cases as well. Decreased NTD risk
has been associated with increased folate
consumption [12]. Folate is a water-soluble B
vitamin that is found naturally in foods, such as
fruits, dark green vegetables, potatoes, beans,
and yeast extract. Folic acid is the synthetic
form of folate found in dietary supplements and
added to enriched flour and grain products,
such as breads, pasta, rice, and cereals [13–15].
When taken before conception, adequate use of
folic acid reduces the incidence of NTDs [16].
In light of this, the US Department of Health
and Human Services (HHS) included two
‘‘healthy people objectives’’ for 2010 related to
NTDs, to reduce the number of NTDs and to
ensure that women have appropriate folate
levels prior to conception [17]. Also, public
health bodies worldwide, such as The Centers
for Disease Control and Prevention (CDC) and
the World Health Organization (WHO),
recommend a daily folic acid intake of 0.4 mg
[18–20] taken at least 1 month before pregnancy
and in the first trimester of pregnancy [5] to
reduce the risk of NTDs (since folic acid only
appears in plasma in subjects receiving doses
above 0.2 mg). There are three public health
strategies for reaching the recommended daily
dose: (1) folic acid supplements combined with
a healthy diet; (2) voluntary fortification of food
with synthetic folic acid; and (3) mandatory
fortification of a staple food [21].
In addition, various public campaigns
educating both healthcare professionals and the
general public have increased international
awareness and helped prevent NTDs [21].
However, whilst studies generally demonstrate
increased awareness, knowledge, and
consumption of folic acid post campaigns [22],
the long-term effects of these campaigns are
unknown and campaigns are limited to a
particular time for a cross-section of their target
audience (from as little as 2 days [23] up to 6 years
[22, 24]). Therefore, the key audience, women of
child-bearing age, may not be reached.
In the US, however, an innovative approach
to increasing folate levels can now be achieved
through the simple use of combined oral
contraceptives (COCs). In 2010, two new
COCs known as Beyaz and Safyral (Bayer
Healthcare Pharmaceuticals, Leverkusen,
Germany) approved by the US Food and Drug
Administration (FDA) were launched. Beside a
label for contraception, these two COCs are
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indicated to raise folate levels for the purpose of
reducing the risk of a neural tube defect in a
pregnancy conceived while taking the product
or shortly after discontinuing the product in
women who choose an oral contraceptive as
their method of contraception.
The combination of health education
programs, recommendations, and food
fortification programs has contributed to
declines in NTD rates (declines of 26–70% over
a period of 15 years). In addition, the reduction
might in part be attributable to secondary
prevention, as the number of terminations due
to improved early diagnosis is rising.
However, the rate of decline has not been as
dramatic as expected [25–29] and despite
measures to reduce NTDs, approximately 4,500
pregnancies every year in Europe result in a live
birth, stillbirth, or termination where a baby or
fetus has been affected by an NTD [29], and in
the US there are 2,500 live births of children
with NTDs each year [30].
Parents (often the sole caregivers) face great
distress at the diagnosis of an NTD. They are
confrontedwitheither thegriefofa terminationor
stillbirth, or the lifelong emotional and financial
challenges of caring for a child with an NTD [31].
Individuals with NTDs that survive, such as those
with SB, are often at risk of psychosocial
maladjustment and have acute, life-long
disabilities [32, 33]. The diverse symptoms can be
associated with NTDs adversely impact quality of
life (QoL), which can manifest in extensive
physical and psychosocial burden [34–42]. There
is also associated economic burden incurred,
including substantial direct medical treatment
costs, direct nonmedical costs (such as special
education and developmental costs), as well as
indirect costs related to increased morbidity and
mortality of patients with NTDs [43].
Health policy makers worldwide increasingly
require insight from caregivers’ and patients’
perspectives, in addition to information about
direct and indirect costs, to demonstrate the
overall impact of a condition [44, 45]. This
paper reviews the human and economic burden
of NTDs on patients and caregivers.
MATERIALS AND METHODS
Search Strategy for Literature Search
Although this review was intended to
demonstrate the impact of all types of NTDs,
since anencephaly is inevitably fatal, the authors’
main focus was on the impact of SB on
patients and caregivers. Using guidelines defined
by the University of York National Health Service
(NHS) Centre for Reviews and Dissemination [46],
a comprehensive search strategy was developed.
The search strategy was implemented using three
electronic databases (PubMed, PsycINFO, and
Embase) to identify relevant studies from
January 1976 to November 2010. The following
clinical terms were used: ‘‘neural tube defects,’’
‘‘NTDs,’’ ‘‘spina bifida,’’ ‘‘anencephaly,’’ and
‘‘meningocele.’’ Patient-reported outcome (PRO)
terms included ‘‘Health-Related Quality of Life,’’
‘‘HRQoL,’’ ‘‘quality of life,’’ ‘‘QoL
symptoms,’’ ‘‘satisfaction,’’ ‘‘body image,’’ ‘‘self-
image,’’ ‘‘emotional,’’ ‘‘physical,’’ ‘‘psychological,’’
‘‘psychosocial,’’ ‘‘self-esteem,’’ ‘‘impact,’’
‘‘relationships,’’ ‘‘caregiver burden,’’ ‘‘family
impact,’’ ‘‘work,’’ ‘‘productivity,’’ ‘‘absenteeism,’’
‘‘presenteeism,’’ ‘‘qualitative,’’ ‘‘interviews,’’
‘‘grounded theory,’’ and ‘‘interpretive
phenomenological analysis.’’ Cost terms
included ‘‘cost,’’ ‘‘economic,’’ ‘‘burden/impact of
illness,’’ ‘‘resource use,’’ ‘‘hospitalization,’’ and
‘‘economic evaluation.’’ ‘‘Family planning,’’
‘‘unplanned pregnancy,’’ ‘‘prenatal care,’’
‘‘abortion,’’ and ‘‘termination’’ were other
keywords used.
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Conference Proceeding Abstract Searches
and Internet Searches
In addition to the electronic database searches,
abstracts from the International Federation for
SB and Hydrocephalus 17th International
Conference were hand-searched to capture
recent information that may have been
presented but not yet published in journals.
Internet searches of family caregiver
associations and societies were also conducted
to access information from grey literature; these
included The Association for SB and
Hydrocephalus (UK), The SB Association (US),
The Scottish SB Association (UK), and SB Family
Support (US).
Inclusion and Exclusion Criteria
Following completion of the search, all titles
and abstracts were screened for possible
inclusion in the study by two independent
researchers (DR and LM). To satisfy the
inclusion criteria, selected abstracts included
an appropriate clinical term and at least one of
the PRO terms or cost terms. The review pool
was restricted to English language studies,
human subjects, and articles published from
January 1976 to November 2010. All letters and
foreign language studies were excluded. The
selected studies contained keywords in the title
or abstract. Studies were excluded only if the
reviewers could be sure that they did not fulfill
the criteria.
Ranking Process
Due to the high number of seemingly relevant
articles, following the inclusion/exclusion
criteria, abstracts were ranked 1, 2, or 3,
according to the following three criteria: (1)
the journal article included terms of interest in
the title and abstract and the terms of interest
were the main focus; (2) the journal article
included the terms of interest as secondary or
exploratory analyses; or (3) the abstract
contained supportive information, but there
was no real data (e.g., there was a background
comment in the introduction or conclusions).
Following the ranking process, articles ranked 1
were included and all others were excluded
from this review.
Currency Conversion
To facilitate comparison of economic studies,
costs were inflated to 2010 US dollar prices
using the Consumer Price Index inflation
calculator (available at www.bls.gov/data/
inflation_calculator.htm) (original costs are
reported in brackets) [47].
RESULTS
Study Selection
The initial literature search resulted in a pool of
4,456 abstracts. The titles and abstracts were
then examined in further detail and a total of
4,288 were excluded for not containing all of
the search terms in the title or abstract
following ranking, or due to duplication
between the databases. Thus, a total of 166
articles were reviewed in detail. The majority of
these papers were US focused.
Impact of SB on Individuals
The impact of SB from the patient’s perspective
has been extensively documented [34, 37–39,
48–70]. Using information from the articles
included in this review, a conceptual model
was developed to demonstrate the relationship
between various factors associated with SB in
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individuals (Fig. 1). A conceptual model
compartmentalizes potential causes,
consequences, and signs and symptoms of the
disease while showing how they are linked with
one another.
Areas of patients’ lives affected include
physical functioning, activities of daily living,
role functioning, bodily pain, vitality, emotional
functioning, mental health, self-esteem, self-
image, social functioning, relationships, and
sexual functioning (see Fig. 1). Long-term
health problems of SB include urinary tract
infections, calculi (kidney stones), and skin
infections. Children with SB also do not grow
and develop at a normal rate [4].
Grimby looked at the differences between
two groups of subjects: one with cerebral palsy,
the other with SB, in their dependence and their
perceived difficulty in performing daily
activities. Subjects in both groups needed help
in basic activities of daily living; however, SB
subjects were more impacted by toileting
problems and lack of bladder and bowel
control than the cerebral palsy subjects. SB
patients also had more mobility problems
related to instrumental daily tasks [71].
Impact on Caregivers
The impact of SB on caregivers has also been
well documented [2, 38, 40, 43, 72–92]. Parents
face great distress upon diagnosis of an NTD in
their child. They are confronted with either the
grief of a termination or stillbirth, or extensive
emotional and financial challenges of caring for
a child with an NTD. Caring for patients with SB
who may have comorbidities can also exert a
substantial burden on caregivers, including the
impact on carer workload, decreased QoL, less
time for work, and additional responsibilities
[93]. Areas of caregivers’ lives affected include
activities of daily living, work impact, time
consumption (including the need to always be
on hand to provide the level of care required for
individuals with SB) [74, 76, 80], parental
responsibilities (including responsibilities to
other children), confidence, feelings and
emotions, mental health, stress, social impact,
psychological adjustment, relationships (with
SB child, siblings, and other members of the
family), social support, coping strategies, and
termination decisions. In one study on
caregivers of children with cerebral palsy or
SB, caring for an affected child took up to 29%
of their waking time [81]. This equated to more
time than spent cooking, cleaning, and doing
the laundry (26%). Leisure activities and work
took up the least amount of their time [81, 94].
Economic Impact of NTDs on Individuals
and Caregivers
The average lifetime direct medical cost per
person with SB ranges from $285,959 ($235,839
in 2002 dollars) [95] to $378,000 ($319,000 in
2003 dollars) [96] in 2010 dollars. This does not
include lifetime direct nonmedical costs (such
as special education and development services)
of $52,570 per person ($43,371 in 2002 dollars)
[95]. A significantly greater economic impact is
related to ‘‘indirect’’ costs due to increased
morbidity and premature mortality in
individuals with an NTD. The average lifetime
indirect cost per person with SB in the US was
estimated to be $432,176 ($356,553 in 2002
dollars) in 2010 dollars, or 57% of the average
total lifetime cost per person with SB [95].
The cost burden on individuals and
caregivers includes out-of-pocket costs, lost
wages/household production due to increased
morbidity and mortality, transportation, and
other nonmedical costs. Very few studies
examine the costs of NTDs from the
perspective of patients and/or caregivers.
6 Neurol Ther (2013) 2:1–12
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Ouyang et al. reported the out-of-pocket cost
burden to privately insured patients in the US.
According to this study, individuals with SB in a
private health insurance plan shared on average
11% of their total health expenditure (8% of
costs for their inpatient care, 11% of costs for
outpatient visits, and 17% of costs for
prescription drugs), which in 2006 was
$40,928 ($34,536 in 2003 dollars) per person
(taken as an average across all age groups of
people with SB) [96].
Despite the potential important contribution
of caregiver time costs to the total cost estimate
of birth defects, only three studies estimated
caregiver time costs related specifically to birth
defects [97–99]. Average reductions of 14 h per
week in paid work time for mothers and 5 h per
week for fathers of children with SB were
reported [99]. Differences in work hours by
caregivers of children with SB translated into
lifetime costs of $162,124 in 2010 dollars
($133,755 in 2002 dollars) using a 3%
discount rate, and an age- and sex-adjusted
earnings profile [99].
DISCUSSION
The results from this review demonstrated the
profound impact of SB on individuals and
caregivers. For patients, this lifetime impact is
apparent in physical, emotional, mental,
educational, sexual, social, and financial
aspects of everyday life. The conceptual model
developed based on the literature highlights the
notable range and variety of the impact on
patients with SB. For caregivers, the emotional
and financial burden along with the toll on
their social lives and work were the greatest
impacts. Caregivers also experience additional
financial burden, including reduced income due
to the necessity of working a reduced number of
hours in paid employment. Patients and
caregivers also incur substantial direct
treatment costs for NTD.
The diverse humanistic impact and economic
burden of SB for individuals and caregivers
emphasizes the importance of providing
substantial care and support to both. In addition,
as outlined earlier, sustained and persistent
education about the benefits of preconceptional
folates is important to help prevent NTDs,
especially since the burden is so often avoidable
with adequate folate consumption at the right
time [21]. However, whilst long-term, effective
health campaigns educating the public about the
benefitsof preconceptional folatemayhelp reduce
NTD risk, given the limitations of such campaigns,
additional strategies, such as different types of
targeted fortification, may be warranted to reduce
this risk even further.
Some limitations of this review deserve
comment. It is important to acknowledge that
this literature review and its findings are based
on published English literature studies that
emerged from searching electronic databases.
Studies were qualitatively discussed, and there
was insufficient data to synthesize the evidence.
Further research could use statistical methods to
explore the net effect of NTDs and treatment.
Furthermore, the majority of the papers in
this review were US focused, especially
economic-related papers. Little is known about
the cost that SB has on individuals’ health-
related QoL in Europe and other regions outside
of the US. Therefore, there is a need for
additional studies in Europe and Asia, and
future studies could be designed to address this.
In addition, while SB is a major type of NTDs,
other rarer forms of NTDs also exist. Although
there is a significant body of evidence to
demonstrate the impact of SB on individuals
and caregivers, this comprehensive literature
review may under-represent the impact of
anencephaly on prospective parents and rarer
Neurol Ther (2013) 2:1–12 7
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types of NTDs, which are also likely to have a
profound effect on individuals and caregivers.
CONCLUSION
Given the substantial range and variety of
humanistic impact and economic burden of
SB, this review highlights the need to provide
care and support to individuals with SB and
their caregivers. Results also emphasize the
importance of effective long-term public
health campaigns and/or newer strategies to
prevent NTDs, such as SB.
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